Granules India Limited
Have updates for this profile? Please contribute data
= Subscriber Access Only
You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.
With Preqin Pro, you gain an unobstructed view of all alternative asset class activity across institutional investors, fund managers, funds, portfolio companies, deals, exits, and service providers.
Granules India Limited - overview
Established
1991
Location
Hyderabad, Telangana, India
Primary Industry
Pharmaceuticals
About
Granules India Limited is a vertically integrated pharmaceutical company focused on producing high-quality Active Pharmaceutical Ingredients (APIs) and finished dosage forms, catering to a global market. Founded in 1991 in Hyderabad, India, Granules India Limited specializes in the production of Active Pharmaceutical Ingredients (APIs) and finished dosage forms. The company was established by Krishna Chigurupati, who has a history in the pharmaceutical sector. Currently, Ramrao KVS and Venu Babu serve as the company's CEOs.
Granules India is a vertically integrated pharmaceutical company specializing in the production of high-quality Active Pharmaceutical Ingredients (APIs), Pharmaceutical Formulations Intermediates (PFIs), and Finished Dosages (FD). The company offers a diverse array of products, including essential medications used for managing chronic conditions, pain relief, and allergy treatments, which serve a wide range of therapeutic areas. Granules India’s products are designed to empower patients and healthcare providers by ensuring access to effective and affordable pharmaceuticals. These offerings are distributed in over 80 countries globally, targeting markets such as North America, Europe, and Asia, where they cater to both healthcare providers and consumers who rely on their medications for daily health needs.
Granules India operates on a B2B model, primarily engaging with global pharmaceutical companies, wholesalers, and retailers for the distribution of its products. This model allows for strategic partnerships and collaborations that enhance supply chain efficiency and regulatory compliance. The company’s revenue for the most recent fiscal year 2024 is USD 544. 37 mn, with an EBITDA of USD 103.
60 mn. The firm’s revenue is driven by the sale of its APIs and finished dosage forms, which are pivotal in the manufacturing of generic drugs. Their flagship products, such as paracetamol and other high-demand pharmaceuticals, contribute significantly to the revenue stream, reflecting the firm’s commitment to delivering quality and value in the pharmaceutical marketplace.
Primary Industry
Pharmaceuticals
Sub Industries
Pharmaceutical Research & Development
Website
www.granulesindia.com
Verticals
Manufacturing
Total Amount Raised
Subscriber access only
Granules India Limited - timeline of key events
Granules India Limited - financials
| Fiscal Year Ended | Mar 31, 2013 | Mar 31, 2014 | Mar 31, 2015 | Mar 31, 2016 | Mar 31, 2017 | Mar 31, 2018 | Mar 31, 2019 | Mar 31, 2020 | Mar 31, 2021 | Mar 31, 2022 | Mar 31, 2023 | Mar 31, 2024 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue (USD) | 7,643,730,000 | 10,958,648,000 | 12,929,224,000 | 14,311,843,000 | 14,352,534,000 | 16,918,483,000 | 22,791,977,000 | 25,986,465,000 | 32,375,428,000 | - | - | - |
| % Revenue Growth (YoY) | - | 43.4% | 18.0% | 10.7% | 0.3% | 17.9% | 34.7% | 14.0% | 24.6% | - | - | - |
| EBITDA (USD) | 862,759,000 | 1,614,261,000 | 2,115,020,000 | 2,792,058,000 | 3,043,508,000 | 3,021,840,000 | 4,522,009,000 | 6,087,414,000 | 8,697,322,000 | - | - | - |
| Operating Income (USD) | 631,913,000 | 1,316,136,000 | 1,588,510,000 | 2,148,759,000 | 2,328,381,000 | 2,259,820,000 | 3,467,175,000 | 4,717,879,000 | 7,182,697,000 | - | - | - |
| Operating Margin | 8.3% | 12.0% | 12.3% | 15.0% | 16.2% | 13.4% | 15.2% | 18.2% | 22.2% | - | - | - |
| % EBITDA Margin | 11.3% | 14.7% | 16.4% | 19.5% | 21.2% | 17.9% | 19.8% | 23.4% | 26.9% | - | - | - |
| NET Income (USD) | 325,673,000 | 752,313,000 | 909,078,000 | 1,184,676,000 | 1,645,191,000 | 1,325,912,000 | 2,364,085,000 | 3,353,983,000 | 5,494,590,000 | - | - | - |
| % Net Margin | 4.3% | 6.9% | 7.0% | 8.3% | 11.5% | 7.8% | 10.4% | 12.9% | 17.0% | - | - | - |
Granules India Limited - employee data
Time to go Pro
Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.